<DOC>
	<DOCNO>NCT02008851</DOCNO>
	<brief_summary>The purpose study determine select renal cell , obtain biopsy patient chronic kidney disease ( CKD ) Type 2 Diabetes ( i.e. , autologous cell ) safely implant back patient .</brief_summary>
	<brief_title>A Phase 1 , Open-label Safety Study NKA Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This Phase 1 safety tolerability study determine NKA , manufacture patient 's renal biopsy tissue , safely implant back kidney patient . Patients must CKD Type 2 Diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients type 2 diabetes mellitus ( T2DM ) . Patients CKD define glomerular filtration rate ( GFR ) 20 50 mL/min/1.73m2 , inclusive . Microalbuminuria explain alternative diagnosis . Microalbuminuria define urinary albumincreatinine ration ( UACR ) ≥ 30 mg/g urine albumin excretion ≥ 30 mg/day 24 hour urine collection . Ongoing treatment ACEi ARB . Patients intolerant may include long stable blood pressure . Systolic blood pressure 105 140 mmHg ( inclusive ) diastolic blood pressure ≤ 90 mmHg . The patient historical data provide reasonable estimate rate progression CKD Type 1 diabetes mellitus ( DM ) . History renal transplant . HbA1c &gt; 10 % Screening . Hemoglobin level &lt; 9 g/dL prior biopsy implant . Known allergy kanamycin structurally similar aminoglycoside antibiotic . Abnormal coagulation status measure activate partial prothrombin time , international normalize ratio ( INR ) , and/or platelet count . Ineligible biopsy ( e.g. , base size cortical depth ) , MRI renal scintigraphy study ( e.g . due hypersensitivity allergy ) accord standard site practice . Not good candidate laparoscopic surgical procedure ( base assessment surgeon perform implant ) , include patient morbidly obese , excessive fat surround kidney , BMI &gt; 45 , otherwise excessive risk serious complication . Clinically significant infection require parenteral antibiotic within 6 week biopsy implantation . Patients small kidney ( average size &lt; 9 cm ) one kidney . Patients rapid decline renal function last 3 month prior biopsy acute kidney injury . Patients follow condition prior biopsy : renal tumor , polycystic kidney disease , renal cyst anatomic abnormality would interfere biopsy implantation procedure ( e.g. , cysts pathway injection implantation ) , hydronephrosis , skin infection propose biopsy site , evidence urinary tract infection . Female subject pregnant , lactate ( breast feed ) plan pregnancy course study . History cancer within past 3 year ( exclude nonmelanoma skin cancer carcinoma situ cervix ) . Life expectancy le 2 year . Any contraindication know anaphylactic severe systemic reaction either human blood product material animal ( bovine , porcine ) origin anesthetic agent . Positive Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) assess . Subjects active tuberculosis ( TB ) require treatment past 3 year . Immunocompromised subject patient receive immunosuppressive agent . Subjects uncontrolled diabetes , incapacitate cardiac and/or pulmonary disorder . History active alcohol and/or drug abuse investigator 's assessment would impair subject 's ability comply protocol . Patients clinically significant hepatic disease . Patients bleed disorder would , opinion Investigator , interfere performance study procedure ; patient take Coumarins ( e.g. , Warfarin ) anticoagulant ( e.g . enoxaparin direct thrombin inhibitor ) . Use investigational product within 3 month biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Neo-kidney augment</keyword>
	<keyword>Regenerative medicine</keyword>
</DOC>